FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
JPMorgan Starts AbCellera Biologics (ABCL) at Overweight, 'feedback bodes well overall'
Tweet Send to a Friend
(Updated - September 29, 2026 10:02 AM EDT)
JPMorgan initiates coverage on AbCellera Biologics (NASDAQ: ABCL) with a Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan initiates coverage on AbCellera Biologics (NASDAQ: ABCL) with a Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
